Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin to Reduce Opioid Abuse Liability and Pain
NCT05761860Phase 1Recruiting
- Sponsor
- University of Florida
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of oxytocin nasal spray in pain (6 arms), sponsored by University of Florida. Primary endpoint: Subject-rated abuse liability at 6 weeks. Started Sep 2023; status: recruiting.
02
Drugs
oxytocin nasal spray
03
Conditions
pain
Beyond the preview
Go deeper on NCT05761860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05761860.